Selection Criteria for Cytoreductive Surgery and Hipec for Treatment of Peritoneal Metastases
International Journal of Orthopedic Surgery & Research · 31.12.2025 · 1 (2)
DOI: 10.33425/3070-3972.1009 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Orthopedic Surgery & Research, online erschienen am 31.12.2025. Verfasst von George Efthymiopoulos und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Peritoneal metastases (PM) from gastrointestinal and gynecological primaries pose a poor prognosis, but cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers potential survival benefits in select cases. This mini-review outlines key selection criteria: low disease burden (Peritoneal Cancer Index 70), manageable comorbidities, and favorable tumor biology. Completeness of cytoreduction (CC-0/1) is essential, best achieved in high volume centers. Preoperative assessment via CT, MRI, PET, and laparoscopy guides decisions, with 3-year survival ranging from 5-10% (gastric PM) to 50-60% (ovarian PM). Multidisciplinary expertise optimizes outcomes while minimizing risks.
Zitieren
APA
Efthymiopoulos, G., Noskova, I., & Spiliotis, J. (2025). Selection Criteria for Cytoreductive Surgery and Hipec for Treatment of Peritoneal Metastases. International Journal of Orthopedic Surgery & Research, 1(2). https://doi.org/10.33425/3070-3972.1009
Vancouver
Efthymiopoulos G, Noskova I, Spiliotis J. Selection Criteria for Cytoreductive Surgery and Hipec for Treatment of Peritoneal Metastases. International Journal of Orthopedic Surgery & Research. 2025;1(2). doi:10.33425/3070-3972.1009
BibTeX
@article{Efthymiopoulos2025,
author = {Efthymiopoulos, George and Noskova, Irina and Spiliotis, John},
title = {Selection Criteria for Cytoreductive Surgery and Hipec for Treatment of Peritoneal Metastases},
journal = {International Journal of Orthopedic Surgery & Research},
year = {2025},
volume = {1},
number = {2},
doi = {10.33425/3070-3972.1009}
}
EUVIMED